Open AccessUbrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
Author(s) -
Edita Navratilova,
Sasan Behravesh,
Janice Oyarzo,
David W. Dodick,
Pradeep Banerjee,
Frank Porreca
Publication year - 2020
Publication title -
cephalalgia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.57
H-Index - 125
eISSN - 1468-2982
pISSN - 0333-1024
DOI - 10.1177/0333102420938652
Subject(s) - sumatriptan , medicine , migraine , sensitization , anesthesia , allodynia , pharmacology , hyperalgesia , calcitonin gene related peptide , burning mouth syndrome , nociception , receptor , neuropeptide , agonist , immunology
Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repeated oral administration of ubrogepant induces latent sensitization relevant to medication overuse headache in rats.